HAVN Life Sciences Inc.
HAVLF
$0.00
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -372.93% | 106.20% | 66.19% | -419.42% | 63.31% |
| Total Depreciation and Amortization | 100.57% | -149.72% | -72.87% | 25.24% | -11.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 117.21% | -132.88% | -71.98% | 1,623.53% | -83.61% |
| Change in Net Operating Assets | 348.59% | 29.60% | 164.09% | -722.31% | 115.99% |
| Cash from Operations | 151.16% | 39.43% | 39.51% | -0.29% | 42.10% |
| Capital Expenditure | -- | -- | -- | 100.00% | -2,133.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | -- | -- | -- | 264.93% | 98.24% |
| Total Debt Issued | -167.33% | -- | -- | -- | -- |
| Total Debt Repaid | -- | 200.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 94.02% | -- | -- |
| Cash from Financing | -161.68% | 932.44% | -103.18% | 5,094.96% | -344.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.13% | 89.36% | -540.63% | 114.10% | 56.88% |